Cassava sciences announces positive interim safety review of simufilam on-going phase 3 trials in patients with alzheimer's disease

Austin, texas, sept. 18, 2023 (globe newswire) --  cassava sciences, inc. (nasdaq: sava), a biotechnology company focused on alzheimer's disease, today announced a positive interim safety review of simufilam in on-going phase 3 clinical trials in patients with alzheimer's disease. a routine, scheduled meeting of a data and safety monitoring board (dsmb) recommended that both of cassava sciences' phase 3 studies of simufilam continue as planned, without modification.
SAVA Ratings Summary
SAVA Quant Ranking